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Study Objectives. We have shown in previous studies that epinephrine 
administered intranasally is a feasible route of administration during 
cardiopulmonary resuscitation (CPR). To promote the absorption of 
epinephrine we administered phentolamine prior to epinephrine and used a 
bile salt as a vehicle to dissolve the epinephrine. The purpose of this study 
was to compare the effect of two different vehicles (bile salt vs surfactant) 
in promoting the absorption of nasally administered epinephrine during 
CPR and to determine their effects on the nasal mucosa. 
Study Design. A randomized, blinded study. 
Setting. A controlled laboratory environment. 
Subjects. Eleven mongrel dogs. 
Interventions. Each dog underwent 3 minutes of unassisted ventricular 
fibrillation (VF) followed by 7 minutes of VF with CPR. Five minutes after 
the start of VF, 10 dogs received intranasal phentolamine 0.25 mg/kg/nostril 
followed 1 minute later by intranasal epinephrine 7.5 mg/kg/nostril. The 
epinephrine was dissolved in a randomly assigned vehicle consisting of 
either taurodeoxycholic acid (group A, bile salt) or polyoxyethylene-9- 
lauryl ether (group B, surfactant). One animal acted as a control and 
received 0.9% sodium chloride nasally. 
Measurements and Main Results. Data from eight dogs (one control) were 
included for analysis. Histology of the nasal cavity demonstrated severe 
multifocal erosion and ulceration of the respiratory epithelium for groups A 
and B compared with the control. The severity was similar between the 
two groups. In addition, no significant differences in plasma epinephrine 
concentrations or blood pressure responses were seen between the groups. 
Conclusion. Based on histology, polyoxyethylene-9-lauryl ether offered no 
advantage over taurodeoxycholic acid in its effect on the nasal mucosa. 
The data available for changes in epinephrine concentration and pressure 
also suggest no difference between the two vehicles in promoting the 
absorption of epinephrine during CPR in an animal model. 
(Pharmacotherapy 1996; 16(6): 1039-1 045) 
Rapid administration of epinephrine by 
intravenous or endotracheal routes during out- 
of-hospital cardiac arrest may be delayed due to 
technical difficulties in endotracheal intubation 
or intravenous catheter injection. In an attempt 
to develop an alternate route of administration in 
which rapid administration of epinephrine is 
possible without requiring technical skills, we 
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evaluated the nasal route of drug administration 
during cardiac arrest.'. ' Previously we showed 
that nasal administration of epinephrine was 
comparable to standard-dose,  intravenous 
epinephrine during ventricular fibrillation (VF) 
and cardiopulmonary resuscitation (CPR) in a 
canine model.' 
In this study we administered phentolamine 
5 mghostr i l  1 minute prior to epinephrine 
administration 14 mghostri l  to reduce nasal 
mucosa vasoconstriction and thereby promote 
absorption. To define the optimum dose 
combination of these two drugs, we recently 
completed a dose-ranging study2 Results suggest 
that 0.25 mg/kg/nostril of phentolamine followed 
by 7.5 mg/kg/nostril of epinephrine provided the 
greatest increase in  plasma epinephrine 
concentrations and blood pressures among the 
doses evaluated. In both studies, a bile salt 
(taurodeoxycholic acid) was added to the 
epinephrine solution to promote further 
absorption. Pilot data from our laboratory 
suggested that bile salts improved the response to 
nasally administered epinephrine.' Other agents 
such as surfactants, however, may be superior in 
promoting epinephrine absorption. A recent 
study comparing bile salts to surfactadts suggests 
that surfactants may be better  promoter^.^ In 
addition, the effect of these agents on the nasal 
mucosa in this model is unknown. Therefore, 
this study was performed to compare the effect of 
bile salt versus surfactant in  promoting the 
absorption of epinephrine, and to assess the 
effects of the two agents on the nasal mucosa 
during VF and CPR in a canine model. 
Methods 
Animal Preparation 
The study was approved by the University of 
Michigan Unit for Laboratory Animal Medicine. 
Ten mongrel dogs, each weighing 20.2 f 3 kg, 
were evaluated in a randomized, blinded study 
comparing the effects of two different vehicles on 
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nasal mucosa and epinephrine absorption. A 
random numbers table was used for random- 
ization. One additional animal served as a control, 
who received normal saline administered nasally 
Intravenous pentobarbital 25 mgkg was used 
to induce anesthesia, which was maintained with 
intravenous pentobarbital 5mg/kg administered 
as needed. However, pentobarbital was not 
administered for a t  least 30 minutes prior to 
experimentation. After induction, each animal 
was placed in a supine position on a surgical 
table with a thermoblanket. A cuffed endo- 
tracheal tube was inserted following intubation. 
Ventilation was started using an Ohio Anesthesia 
Ventilator (Ohio Medical Products, Madison, 
WI); the initial tidal volume was 10-15 ml/kg 
with a respiratory rate of 15 breathdminute. 
After tracheal intubation, the femoral artkries and 
vein were surgically exposed along with the right 
jugular vein.' A 6-F pigtailed catheter was placed 
in the aortic arch and right ventricle for aortic 
pressure measurements and induction of VF, 
respectively. Another 6-F catheter was placed 
into the right atrium for measurement of right 
atrial pressures. The position of the catheters 
was determined by pressure measurements and 
waveforms and, if necessary, confirmed at the end 
of the study by necropsy. All dogs received a 
heparin 150-unit/kg intravenous bolus dose 
following catheter placement to help maintain 
catheter patency. 
Pressures from the aorta and right atrium were 
measured and recorded throughout the study. 
The pressures were measured with a calibrated 
Gould P23 transducer and recorded with a Gould 
eight-channel RS 3800 graphic recorder (Gould 
Inc., Cleveland, OH). A single-lead electro- 
cardiogram was also recorded by the RS 3800 
graphic recorder. 
Before the start of the study, arterial blood 
gases were stabilized by altering the respiration 
rate or tidal volume to achieve and maintain an 
arterial pH of 7.4 f 0.1 and a partial pressure of 
carbon dioxide (pCOz) of 40 * 10 mm Hg. 
Arterial blood gas measurements were taken at 
baseline prior to the start of VF, again following a 
20-minute stabilization period, and 5 minutes 
after the start of CPR. All blood gas samples 
were placed on ice and analyzed using a 
Radiometer AB L 2 (Acid -B a s e Labor a t  o r y, 
Cleveland, OH). 
Experimental Procedure 
Following induction of anesthesia, insertion of 
NASAL EPINEPHRINE Bleske et al 1041 
monitoring catheters, and obtainment of baseline 
measurements, VF was induced by a 24-mA, 60- 
Hz electric current through a pacing wire placed 
in the right ventricle. After 3 minutes of 
unassisted VF, CPR was started and maintained 
for 7 minutes. A pneumatic chest compression 
device (Thumper; Michigan Instruments, Grand 
Rapids, MI),  set at a chest compression rate of 
80/minute with a chest compression duration of 
0.5 second, was used to perform CPR. Following 
every fifth compression, diastole was prolonged 
by 0.5 second, and the lungs were inflated to an 
inspiratory pressure of approximately 15 cm of 
H 2 0  with 100% oxygen by a synchronized, 
pressure-limited ventilator (Thumper). The 
compression force was set initially to produce a 
stable coronary perfusion pressure gradient 
(aortic-right atrial mid-diastolic pressure) during 
the relaxation phase between 10 and 20 mm Hg. 
This same compression force was maintained 
throughout the study period. 
After 2 minutes of CPR (a total of 5 minutes of 
VF) ,  phentolamine 0.25 mg/kg/nostril was 
administered nasally followed 1 minute later by 
epinephrine 7.5 mg/kg/nostril. The vehicle in 
which epinephrine was dissolved (bile salt vs 
surfactant) was assigned in a randomized and 
blinded manner. The dose of phentolamine and 
epinephrine used was based on our previous 
dose-ranging study2 
After 7 minutes of CPR (a total of 10 minutes 
of VF), defibrillation with 7 J k g  of energy was 
attempted (Model 604-A; MennedGreatbach 
Electronics Inc., Clarence, NY). If VF did not 
terminate, CPR was continued with additional 
defibrillation attempts using 10 J/kg every 30 
seconds, if necessary, up to 10 minutes from the 
first defibrillation. Resuscitation was defined as 
the attainment of an organized cardiac rhythm 
with a systolic blood pressure of 60 mm Hg or 
more for at least 2 minutes within a 12-minute 
period from the first defibrillation. 
Arterial plasma epinephrine concentrations 
were obtained prior to the administration of 
epinephrine and every minute thereafter until the 
first defibrillation attempt.  Samples were 
collected and placed into chilled heparinized 
tubes and centrifuged immediately. All samples 
were stored at -70°C until assayed. Epinephrine 
concentrations were determined by high- 
performance liquid chromatography with 
electrochemical d e t e ~ t i o n . ~  Dihydroxy- 
benzylamine (Sigma Chemical Company, St. 
Louis, MO) was added to each sample as the 
internal standard. The interday coefficient of 
variation for epinephrine was 6.8%. 
A t  the end of the study, each dog was 
euthanized with potassium chloride to effect, and 
two animals from each group were evaluated for 
changes in the histology of the nasal mucosa. 
Specifically, the maxilla and nasal cavity were 
removed, fixed in 10% buffered formalin, and 
decalcified with Decalcifying Solution (Baxter, 
McGraw Hill, IL).  Four representative cross- 
sections of the nasal cavity were made, processed, 
embedded in paraffin, sectioned a t  5 p, stained 
with hematoxylin and eosin, and evaluated by a 
veterinary pathologist. 
Animals were excluded from analysis if the 
position of the Thumper piston could not be 
maintained on the chest as determined by the 
blinded investigator performing CPR or if there 
was fluctuation in coronary perfusion pressure 
resulting from a change in Thumper position. In 
addition, animals were excluded if a minimum 
coronary perfusion pressure of 5 mm Hg could 
not be obtained before epinephrine administration. 
The exclusion criteria were required because 
inclusion of these animals with variable or 
inadequate coronary perfusion pressure caused 
by poor chest configuration or CPR technique 
would potentially bias the data since the end 
points of the study include changes in pressure 
and survival. 
Drug Preparation and Administration 
Phentolamine mesylate powder was dissolved 
in 0.9% sodium chloride so that 0.95 ml would 
deliver the required amount of drug. Racemic 
epinephrine hydrochloride powder was dissolved 
in either a 1% taurodeoxycholic acid solution 
(group A, bile salt) or a 1% polyoxyethylene-9- 
lauryl ether solution (group B, surfactant), 
depending on randomization, so that 0.95 ml 
would deliver the required amount of drug. 
Taurodeoxycholic acid and the polyoxyethylene- 
9-lauryl ether were dissolved in 0.9% sodium 
chloride with HEPES 0.5% added as a buffer (pH 
7.4). All chemicals were obtained from Sigma 
Chemical Company (St. Louis, MO). 
Employing a previously described technique, 
the drug was administered intranasally by 
inserting a 21-gauge intravenous catheter 
without the needle (Angiocath; Deseret Medical, 
Inc., Sandy, UT) into each nostril and attaching a 
l-ml syringe.', 2, To help facilitate dispersion of 
drug onto the nasal mucosa, the catheter tip .was 
ligated, and six holes were made within a 1.5-cm 
space from the tip using a 26-gauge needle. 
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Table 1. Arterial Blood Gas Values (mm Hg) at Baseline 
and at 5 Minutes of CPR 
uH wco, wo, 
B a s s  
~ ~ ~ 
Group A 7.35 * 0.02 37 * 6 610 * 28 
Group B 7.39 * 0.03 36 * 4 590 * 68 
Group A 7.46 * 0.09 19.9 i: 4.8 442 * 121 
Group B 7.47 i: 0.08 22.8 f 1.8 524 * 49 
CPR 
Data Analysis 
Histological evaluation and measurement of 
pressure waveforms (average of five readings/ 
measurement) were determined by a blinded 
investigator. Statistical comparison of the 
treatment groups was performed using Student's t 
test with Bonferroni's correction, and Fisher's 
exact test where appropriate. Data are reported 
as mean and standard deviation. 
Results 
Ten dogs were randomized, and of these, eight 
(one control) were included for analysis. Two 
dogs from group A (bile salt) and one dog from 
group B (surfactant) were excluded fiom analysis 
because of poor chest configuration and CPR 
technique as defined in the previous section. 
Arterial blood gas results at baseline and during 
CPR were similar between the two groups and 
are listed in Table 1. 
Normal histology of nasal turbinate as seen in 
the control dog (Figure 1) demonstrates normal 
ciliated columnar epithelial cells and intact 
basement membrane. The columnar epithelial 
cells are attached to the basement membrane and 
closely packed. Compared with the control dog 
(Figure l), the nasal mucosa for both group A 
(Figure 2) and  group B (Figure 3) dogs 
demonstrates severe multifocal erosion of the 
nasal epithelium. The columnar epithelial cells 
show significant disruption and deciliation with 
only remnants of the cells remaining. No intact 
epithelial cells are observed. Ulceration of the 
basement membrane is also seen in Figure 3 .  
These effects were noted especially in  the 
turbinates projecting into the nasal cavity. By 
visual inspection, the severity of damage between 
group A and B was similar. 
Both group A and group B demonstrated 
increases in plasma epinephrine concentrations 
over time with no significant differences (p>0.25) 
between the two groups even though group A 
had over 2 times the observed concentrations of 
epinephrine (Table 2). In addition, when the 
data were adjusted for baseline differences 
(analyzed for percentage change) at the time of 
Figure 1. Normal turbinate mucosa from control dog (x 
470). I 
" 
Figure 2. Severe erosion of turbinate mucosa from Group A 
dog (x 470). 
Figure 3. Severe erosion of turbinate mucosa from Group B 
dog (x 470). Note the focus of ulceration (arrowhead). 
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Table 2. Mean Plasma Epinephrine Concentration (pg/ml) during CPR 
Before Epinephrine Minutes After Epinephrine Administration 
Administration 1 2 3 4 
5905 * 1259 11,936 * 7823 129,364 * 159,566 314,153 * 352,515 397,486 * 424,367 Group A 
Group B 12,456 _+ 9,764 15,320 * 6067 47,427 * 61,174 78,373 * 96,484 179,379 * 257,550 
Table 3.  Mean Pressures (mm Hg) Before and During CPR 
At Time of 
Phentolamine Epinephrine Administration Time (min) 
Baseline Administration 0 1 2 3 4 
Group A 
AOS 120 * 15 42 * 21 52.7 * 22 54 rt 24 54 24 51.4 * 22 49.4 * 20 
AOD 90 * 9 16.5 * 5 20.1 * 8.2 21 rt 8.5 20* 11 19.3 i 10 19.3 2 10 
CPP 88 * 8 15.3 * 5 15.4 f 3 17.3 * 3.5 16.6 k 7 15.9 i 6 16.3 * 7 
AOS 115 * 21 49.1 * 12 51.3 * 15 53.8 * 16 54.9 i 18 55.3 * 16 51.8 * 19 
AOD 81 * 16 26 * 7 26.7 * 8 28.1 rt 9 28.8 * 11 27.9 * 12 27.3 f 13 
CPP 78 * 14 18.3 * 6 18.5 * 7 20.3 * 10 20.6 k 13 20.4 * 14 21 * 15 
Group B 
~ 
AOS = aortic systolic pressure; AOD = aortic diastolic pressure; CPP = coronary perfusion pressure 
epinephrine administration, no significant 
differences were seen at any time point. The time 
to maximum change in epinephrine concen- 
trations for each dog in each group occurred at 
the last time point. 
Mean pressures over time, at baseline and 
during CPR, are shown in Table 3. No significant 
differences were seen at any time point. In 
addition, when the data were adjusted for 
baseline differences (analyzed for percentage 
change) at the time of epinephrine administration, 
no significant differences were seen at any time 
point (p>0.33). Overall, 2 of 3 animals in group 
A and 2 of 4 animals in group B had an increase 
in pressure during the study. The peak change in 
coronary perfusion pressure in these animals was 
similar between the two groups, 33% change in 
group A versus 38% change in  group B. 
Resuscitation rate favored group B; 3 of 4 of the 
group B animals were resuscitated and 0 of 3 in 
group A (p=0.14). 
Discussion 
The results of this study demonstrated that 
nasal administration of epinephrine, regardless of 
the vehicle used (bile salt versus surfactant), 
caused significant cellular disruption of the nasal 
mucosa. In addition, both vehicles increased 
plasma epinephrine concentrations and blood 
pressures to a similar degree. These limited data 
suggest that the effects of polyoxyethylene-9- 
lauryl ether are similar to and offer no advantage 
over taurodeoxycholic acid in enhancing the 
absorption of nasally administered epinephrine 
during CPR. 
Our previous studies showed that the nasal 
administration of epinephrine during an  
emergency situation may be feasible; however, 
the effect of this route of administration on the 
nasal mucosa was unknown.',  ' This study 
demonstrated that nasal administration of 
epinephrine, regardless of the vehicle used, 
caused significant cellular damage including loss 
of the epithelial layer and disruption of the 
basement membrane. These results appear to be 
similar to a previous rat study in which these 
vehicles were e ~ a l u a t e d . ~  The mechanism by 
which bile salts and surfactants work as 
promoters is unknown, but may include cellular 
disruption such as formation of temporary 
membrane pores, relaxation of the tight junctions 
between cells, and actual destruction of 
The data from this study strongly suggest that 
taurodeoxycholic acid and polyoxyethylene-9- 
lauryl ether promote the absorption of 
epinephrine in this model by altering, in part, the 
integrity of the cellular structures of the nasal 
mucosa. 
The long-term morbidity that may occur from 
the administration of intranasal epinephrine with 
either vehicle is unknown. However, i t  is 
interesting to note that polyoxyethylene-9-lauryl 
ether (0.1-1%) has been used to promote the 
absorption of intranasal insulin in humans 
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without significant adverse  effect^.^ The reason 
for the limited adverse effects observed may 
relate to the model used. In the previous study 
in humans, the insulin and vehicle were allowed 
to be “washed” away by normal physiological 
processes that may have limited cellular disrup- 
tion of the nasal m u c o ~ a . ~ ’ ~  In contrast, the drug 
and vehicle in  this current study were 
administered in a low flow state followed by 
euthanasia and removal of the nasal mucosa over 
a 30- to 60-minute time period. The damage to 
the nasal mucosa may potentially be less severe if 
spontaneous circulation is returned, allowing 
removal of the drug and vehicle by normal 
physiological processes or if the nasal passage is 
“washed” with normal saline. Finally, the degree 
of morbidity associated with intranasal 
administration of epinephrine may be justified if 
a decrease in mortality can be achieved with this 
method. 
Each group demonstrated increased plasma 
epinephrine concentrations from baseline, with 
group A demonstrating the greatest elevations. 
This difference was not statistically significant 
(p>0.25) and may be due to the high degree of 
variability in epinephrine levels observed in the 
study leading to a type I1 error. To detect a 
difference between groups at the last time point, 
approximately 60 animals would need to be 
studied (a=0.05, p=0.2). The high degree of 
variability can be accounted for by one animal in 
each group that demonstrated tremendous 
increases in epinephrine concentrations from 
baseline (881,850 pg/ml and 557,376 pg/ml for 
groups A and B, respectively). When these 
animals are excluded from analysis, group A still 
demonstrates the highest increase in epinephrine 
concentrations (153,024 f 40,071 pg/ml vs 
50,978 f 24,035 pg/ml, p=0.094). These 
elevations in  epinephrine concentrations 
observed are probably due to the absorption of 
epinephrine from the nasal mucosa since in our 
previous study epinephrine concentrations 
increased by only 35,000 pg/ml in the group with 
the smallest amount of epinephrine administered 
(0.075 mgkg).’ 
As with the epinephrine concentration results, 
both groups demonstrated similar changes in 
blood pressures with no clinical or statistical 
difference between the two groups (p>0.22). 
Overall, neither group demonstrated impressive 
increases in blood pressures as had been shown 
in previous studies,’, ’ due perhaps to the limited 
number of animals studied. However, individual 
animals did show increases in peak pressures as 
pointed out in the results section. 
The obvious limitation of this study is the low 
number of animals studied, which does not allow 
us to evaluate definitively the effects of these two 
vehicles on changes in epinephrine concentrations 
or pressure. However, based on our experience 
in this area, if polyoxyethylene-9-lauryl ether 
were going to increase epinephrine absorption to 
a greater degree compared with taurodeoxycholic 
acid, a clear trend or even statistical significance 
would have been seen with the number of 
animals studied. In fact, excluding the one 
outlier from each group as discussed above, a 
statistical difference was nearly observed, 
p=0.094, suggesting that taurodeoxycholic acid 
enhanced the absorption of epinephrine more 
than polyoxyethylene-9-lauryl ether. Furthermore, 
a power analysis on these data suggests that less 
than four animals in each group would need to 
be studied 40 demonstrate statistical difference 
between the two groups. Based on these findings 
and our experience, we believe that polyoxy- 
ethylene-9-lauryl ether does not enhance the 
nasal absorption of epinephrine to a greater 
degree than taurodeoxycholic acid. 
Despite the apparent limitation on evaluating 
epinephrine concentrations, this study does 
allow for the evaluation of histological effects on 
the nasal mucosa, a primary purpose of the study. 
One limitation on the histological evaluation is 
the time frame between the end of the study and 
the removal of the nasal mucosa. Less damage to 
the nasal mucosa may have occurred if dissection 
time were faster or if the nasal cavity were 
washed with normal saline. Further studies 
would be needed to determine the effect of time 
and washing on the degree of damage to the nasal 
mucosa. In addition, it would be interesting to 
determine the effect of epinephrine alone on the 
nasal mucosa to assess its ability to affect the 
nasal mucosa. Theoretically, epinephrine, with 
its potent vasoconstricting effects along with 
underlying hypoperfusion during CPR, may 
cause significant damage to the nasal mucosa. 
Another potential limitation of this study, which 
we have addressed in previous articles,’, ’ is the 
use of an animal model to study nasal drug 
absorption. 
In conclusion, this study demonstrated that 
both taurodeoxycholic acid and polyoxyethylene- 
9-lauryl ether caused significant damage to the 
nasal mucosa with no major visual difference 
between the two agents. In addition, limited data 
suggest that the effectiveness of each agent in 
promoting the absorption of epinephrine as 
NASAL EPINEPHRINE Bleshe et a1 1045 
determined by plasma epinephrine concentrations 
and pressure changes are similar. 3. 
4. 
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